CONTINENTAL CARBONIC PRODUCTS, INC.
PharmaCONTINENTAL CARBONIC PRODUCTS, INC. is a pharmaceutical company with 1 FDA-approved products.
CONTINENTAL CARBONIC PRODUCTS, INC.'s Key Drugs
CONTINENTAL CARBONIC PRODUCTS, INC.'s core commercial portfolio centers on CARBON DIOXIDE, USP — its most strategically important drugs approved in the last 15 years.
CONTINENTAL CARBONIC PRODUCTS, INC.'s Recent FDA Approvals
CONTINENTAL CARBONIC PRODUCTS, INC. secured 6 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
CONTINENTAL CARBONIC PRODUCTS, INC.'s Therapeutic Areas
Disease areas where CONTINENTAL CARBONIC PRODUCTS, INC. has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
CONTINENTAL CARBONIC PRODUCTS, INC. Pipeline Snapshot
Active clinical trials for CONTINENTAL CARBONIC PRODUCTS, INC. across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CARBON DIOXIDE, USP leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2022-02-25
- Latest
- 2022-02-25
- Applications
- 1